Using Tamsulosin to Reduce Urinary Retention After Thoracic Surgery
Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery
This study is testing if taking Tamsulosin for a week before thoracic surgery can help older men avoid problems with urination afterwards.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 46 (estimated) |
| Ages | 55 Years and up |
| Sex | Male |
| Sponsor | Hackensack Meridian Health Academic / other |
| Locations | 4 sites (Brick, New Jersey and 3 other locations) |
| Trial ID | NCT05657990 on ClinicalTrials.gov |
What this trial studies
This feasibility study investigates whether Tamsulosin can reduce the incidence of postoperative urinary retention (POUR) in older men undergoing thoracic oncological surgery. The study focuses on men aged 55 and older who are scheduled for surgery and will take Tamsulosin for seven days prior to the procedure. Researchers will measure spontaneous voids and assess residual urine post-surgery to evaluate the effectiveness of the treatment. The goal is to determine if Tamsulosin can improve urinary function and reduce complications associated with POUR.
Who should consider this trial
Good fit: Ideal candidates are males aged 55 and older scheduled for thoracic oncological surgery.
Not a fit: Patients currently using Tamsulosin or those with certain medical conditions such as hypotension or heart failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of urinary retention and related complications in older men after thoracic surgery.
How similar studies have performed: Previous studies have indicated that Tamsulosin may effectively reduce urinary retention, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males * ≥55 years old * Planned thoracic oncological surgical procedure of a video assisted oncological surgical procedure for suspected or confirmed cancer. * Surgery scheduled more than 7 days from the time of consent Exclusion Criteria: * Using Tamsulosin already * Known allergy to Tamsulosin or sulfa drugs * Current use of Boceprevir * Resting systolic blood pressure \<100 * Orthostatic hypotension of \>20mm Hg systolic and/or 10mm Hg diastolic pressure from sitting to standing (after 2 minutes of standing) as measured at the time of consent * Known history of hypotension * Known diagnosis of congestive heart failure (CHF) and valvular heart disease * History of prior prostate surgery (prostatectomy, trans-urethral resection)
Where this trial is running
Brick, New Jersey and 3 other locations
- Ocean University Medical Center — Brick, New Jersey, United States (Recruiting)
- South Ocean University Medical Center — Manahawkin, New Jersey, United States (Recruiting)
- Jersey Shore University Medical Center — Neptune City, New Jersey, United States (Recruiting)
- Riverview Medical Center — Red Bank, New Jersey, United States (Recruiting)
Study contacts
- Principal investigator: Thomas Bauer, MD — Hackensack Meridian Health
- Study coordinator: Denise Theiler, RN
- Email: Denise.Theiler@hmhn.org
- Phone: 7327763301
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.